Search Within

Zachary Drew Epstein-Peterson

Formats
  1. Meeting Abstract (56)
  2. Journal Article (21)
  3. Review (9)
  4. Research Letter (7)
  5. Editorial (1)
Groups
  1. Hematologic Malignancies, Division of (94)
  2. Hematology-Oncology Fellows (94)
  3. Department of Medicine (90)
  4. Center for Hematologic Malignancies (89)
  5. Lymphoma (69)
  6. Population Sciences Research Program (54)

More Groups

People
  1. Steven Horwitz (47)
  2. Alison Moskowitz (45)
  3. Anita Kumar (43)
  4. Gilles Salles (38)
  5. Maria Palomba (38)
  6. Andrew Zelenetz (35)

More People

Years
  1. 2025 (8)
  2. 2024 (23)
  3. 2023 (24)
  4. 2022 (10)
  5. 2021 (8)
  6. 2020 (7)

More Years

Publications
  1. Blood (49)
  2. Blood Advances (5)
  3. Haematologica (5)
  4. Hematological Oncology (4)
  5. Leukemia Research (4)
  6. American Journal of Hematology (3)

More Publications

Publishers
  1. American Society of Hematology (55)
  2. Wiley Blackwell (6)
  3. Ferrata Storti Foundation (5)
  4. Elsevier Ltd (4)
  5. Nature Publishing Group (4)
  6. John Wiley & Sons, Inc. (3)

More Publishers

Results (94)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 1 trial of KT‐333, a STAT3 degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia and solid tumors
    Meeting Abstract

    Smith, S.; Olszewski, A.; Starodub, A. N.; Stevens, D. A.; Feldman, T.; Porcu, P.; Epstein-Peterson, Z.; Huen, A.; Pinter‐Brown, L.; Mattour, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma
    Meeting Abstract

    Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Long‐term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A. M.; Noy, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia
    Journal Article

    Stahl, M.; Derkach, A.; Farnoud, N.; Bewersdorf, J. P.; Robinson, T.; Famulare, C.; Cho, C.; Devlin, S.; Menghrajani, K.; Patel, M. A.; more...
    American Journal of Hematology (2023)

    Fulltext@MSK | Save
  • Trial-in-progress: AMC 112: Axicabtagene ciloleucel in relapsed or refractory HIV-associated aggressive B-cell non-Hodgkin lymphoma (NCT05077527)
    Meeting Abstract

    Epstein-Peterson, Z. D.; Lee, J. Y.; Barta, S. K.; Palomba, M. L.; Noy, A.
    Blood (2022)

    Fulltext@MSK | Save
  • Characterization of a large cohort of patients with nodal marginal zone lymphoma shows prolonged survival, time-to-treatment, and time-to-transformation
    Meeting Abstract

    Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing
    Meeting Abstract

    Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Identifying primary refractory disease and early relapses in peripheral T-cell lymphoma using baseline characteristics, minimal residual disease, and mutational profiling
    Meeting Abstract

    Stuver, R.; Haynie, H.; Epstein-Peterson, Z. D.; Johnson, W. T.; Khan, N.; Mazloom, A.; Moskowitz, A. J.; Drill, E.; Horwitz, S. M.
    Blood (2022)

    Fulltext@MSK | Save
  • Outcomes for patients with relapsed and refractory peripheral T-cell lymphoma in the 21st century by relapse status, salvage therapy, and receipt of allogeneic transplant
    Meeting Abstract

    Stuver, R.; Epstein-Peterson, Z. D.; Johnson, W. T.; Khan, N.; Sauter, C. S.; Scordo, M.; Shah, G. L.; Moskowitz, A. J.; Horwitz, S. M.
    Blood (2022)

    Fulltext@MSK | Save